Please use this identifier to cite or link to this item:
|Title:||AN EVALUATION OF THE SHIELDING EFFECTIVENESS OF LEAD APRONS USED IN CLINICS FOR PROTECTION AGAINST IONISING RADIATION FROM NOVEL RADIOISOTOPES.||Austin Authors:||Deb, Pradip;Jamison, Robert;Mong, Lisa;U, Paul||Affiliation:||Peter MacCallum Cancer Centre, Melbourne 8006, Australia
Austin Hospital, Heidelberg, Victoria 3084, Australia
School of Medical Sciences, RMIT University, Bundoora West Campus, Victoria 3083, Australia firstname.lastname@example.org.
|Issue Date:||5-Apr-2015||Publication information:||Radiation Protection Dosimetry 2015; 165(1-4): 443-7||Abstract:||The purpose of this study is to evaluate the effectiveness of personal radiation shields currently worn in hospital and other diagnostic environments. This study was performed with four different radioisotopes;(18)F, (99m)Tc, (124)I and (131)I. (18)F results showed a decrease in dose with 0.5-mm Pb shielding but the reduction provided does not warrant its use clinically. (124)I testing demonstrated that dose enhancement can occur in greater shield thicknesses. PET isotope (124)I can be adequately shielded using 0.25-mm Pb equivalent aprons but any higher thickness increase the wearer's dose. As a result more shielding does not always equal more protection. The (131)I test showed that no dose reduction occurred, even when tested with up to 1.25-mm Pb equivalent shielding. Novel radioisotopes being used in the laboratory and clinic should be individually tested as each requires specific shielding testing.||Gov't Doc #:||25848112||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12723||DOI:||10.1093/rpd/ncv065||URL:||https://pubmed.ncbi.nlm.nih.gov/25848112||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 2, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.